Drug intelligence / Profile preview

RJB-c0207

Development stage: Preclinical
Lead developer: Rejuvenate Bio
Modality: Gene Therapies
Administration: Intravenous

Overview

RJB-c0207 is a gene therapy candidate developed by Rejuvenate Bio for the treatment of osteoarthritis in animals. It is designed to deliver the gene encoding αKlotho (Alpha-Klotho), a protein with significant anti-aging, anti-inflammatory, and chondroprotective properties. By restoring or enhancing αKlotho levels within the joint environment, the therapy aims to slow the progression of cartilage degeneration and alleviate the symptoms of osteoarthritis. The program is currently in the discovery phase and is being developed in partnership with a leading global animal health company.

Targets

KL (Klotho Protein)

Beyond the preview

Go deeper on RJB-c0207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJB-c0207.

Explore the full profile